Terms: = Brain cancer AND CXCR4, D2S201E, 7852, ENSG00000121966, P61073, NPYY3R, NPY3R, HM89, NPYRL, LESTR, HSY3RR, LCR1, fusin, WHIM, NPYR, FB22, CD184
286 results:
1. Targeting the CXCL12/cxcr4 pathway to reduce radiation treatment side effects.
Chaudary N; Hill RP; Milosevic M
Radiother Oncol; 2024 May; 194():110194. PubMed ID: 38447871
[TBL] [Abstract] [Full Text] [Related]
2. Whole-exome sequencing has revealed novel genetic characteristics in intracranial germ cell tumours in the Chinese.
Huang X; Huang J; Zhou X; Zhang C; Ding X; Wong PJC; Wang Y; Zhang R
Histopathology; 2024 Jun; 84(7):1199-1211. PubMed ID: 38409885
[TBL] [Abstract] [Full Text] [Related]
3. Integrated Bioinformatic Analysis and Validation Identifies Immune Microenvironment-Related Potential Biomarkers in Alzheimer's Disease.
Yang F; Zhang N; Ou GY; Xu SW
J Prev Alzheimers Dis; 2024; 11(2):495-506. PubMed ID: 38374756
[TBL] [Abstract] [Full Text] [Related]
4. Bone Marrow Stromal Cells inhibited the growth and metastasis of human U87 cells through delivering exosomal miR-506.
Zhang L; Ding Y; Zhou W; Xu X; Zheng J
Medicine (Baltimore); 2023 Dec; 102(49):e36582. PubMed ID: 38065867
[TBL] [Abstract] [Full Text] [Related]
5. Differential requirements for CD4+ T cells in the efficacy of the anti-PD-1+LAG-3 and anti-PD-1+CTLA-4 combinations in melanoma flank and brain metastasis models.
Phadke MS; Li J; Chen Z; Rodriguez PC; Mandula JK; Karapetyan L; Forsyth PA; Chen YA; Smalley KSM
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056899
[TBL] [Abstract] [Full Text] [Related]
6. Chemokine receptor cxcr4 interacts with nuclear receptor Nur77 and promote glioma invasion and progression.
Dai Y; Yu C; Zhou L; Cheng L; Ni H; Liang W
Brain Res; 2024 Jan; 1822():148647. PubMed ID: 37890573
[TBL] [Abstract] [Full Text] [Related]
7. Implantable SDF-1α-loaded silk fibroin hyaluronic acid aerogel sponges as an instructive component of the glioblastoma ecosystem: Between chemoattraction and tumor shaping into resection cavities.
Molina-Peña R; Ferreira NH; Roy C; Roncali L; Najberg M; Avril S; Zarur M; Bourgeois W; Ferreirós A; Lucchi C; Cavallieri F; Hindré F; Tosi G; Biagini G; Valzania F; Berger F; Abal M; Rousseau A; Boury F; Alvarez-Lorenzo C; Garcion E
Acta Biomater; 2024 Jan; 173():261-282. PubMed ID: 37866725
[TBL] [Abstract] [Full Text] [Related]
8. Stem-like signatures in human meningioma cells are under the control of CXCL11/CXCL12 chemokine activity.
Barbieri F; Bajetto A; Dellacasagrande I; Solari A; Würth R; Fernandez V; Rancati S; Ceresa D; Appolloni I; De Luca G; Dono M; Nozza P; Schiapparelli P; Gambaro M; Fiaschi P; Gaggero G; Costanzo N; Thellung S; Malatesta P; Pagano A; Zona G; De Pietri Tonelli D; Florio T
Neuro Oncol; 2023 Oct; 25(10):1775-1787. PubMed ID: 37074930
[TBL] [Abstract] [Full Text] [Related]
9. cxcr4 antagonists disrupt leukaemia-meningeal cell adhesion and attenuate chemoresistance.
Jonart LM; Ostergaard J; Brooks A; Fitzpatrick G; Chen L; Gordon PM
Br J Haematol; 2023 May; 201(3):459-469. PubMed ID: 36535585
[TBL] [Abstract] [Full Text] [Related]
10. cxcr4-targeted nitric oxide nanoparticles deliver PD-L1 siRNA for immunotherapy against glioblastoma.
Hsieh HT; Huang HC; Chung CW; Chiang CC; Hsia T; Wu HF; Huang RL; Chiang CS; Wang J; Lu TT; Chen Y
J Control Release; 2022 Dec; 352():920-930. PubMed ID: 36334859
[TBL] [Abstract] [Full Text] [Related]
11. cxcr4 expression is associated with proneural-to-mesenchymal transition in glioblastoma.
Khan AB; Lee S; Harmanci AS; Patel R; Latha K; Yang Y; Marisetty A; Lee HK; Heimberger AB; Fuller GN; Deneen B; Rao G
Int J Cancer; 2023 Feb; 152(4):713-724. PubMed ID: 36250346
[TBL] [Abstract] [Full Text] [Related]
12. Molecular profile reveals immune-associated markers of medulloblastoma for different subtypes.
Chen J; Kang Z; Li S; Wang C; Zheng X; Cai Z; Pan L; Chen F; Li W
Front Immunol; 2022; 13():911260. PubMed ID: 35967388
[TBL] [Abstract] [Full Text] [Related]
13. Defibrotide suppresses brain metastasis by activating the adenosine A2A receptors.
Dong C; Zhu L; Yue X; Sun Z; Wang C; Ye Z; Pan B
Anticancer Drugs; 2022 Nov; 33(10):1081-1090. PubMed ID: 35946567
[TBL] [Abstract] [Full Text] [Related]
14. CXC Motif Chemokine Receptor Type 4 Disrupts Blood-brain Barrier and Promotes brain Metastasis Through Activation of the PI3K/AKT Pathway in Lung cancer.
Zhu L; Yang F; Wang G; Li Q
World Neurosurg; 2022 Oct; 166():e369-e381. PubMed ID: 35817351
[TBL] [Abstract] [Full Text] [Related]
15. Identification and characterization of sex-dependent gene expression profile in glioblastoma.
Qin S; Yuan Y; Liu H; Pu Y; Chen K; Wu Y; Su Z
Neuropathology; 2023 Feb; 43(1):72-83. PubMed ID: 35789505
[TBL] [Abstract] [Full Text] [Related]
16. Targeting cxcr4 to suppress glioma-initiating cells and chemoresistance in glioma.
Wu Y; Hu Y; Tang L; Yin S; Lv L; Zhou P
Cell Biol Int; 2022 Sep; 46(9):1519-1529. PubMed ID: 35731168
[TBL] [Abstract] [Full Text] [Related]
17. Glioblastoma-associated microglia-derived exosomal circKIF18A promotes angiogenesis by targeting FOXC2.
Jiang Y; Zhao J; Xu J; Zhang H; Zhou J; Li H; Zhang G; Xu K; Jing Z
Oncogene; 2022 Jun; 41(26):3461-3473. PubMed ID: 35637250
[TBL] [Abstract] [Full Text] [Related]
18. Systemic Delivery of an Adjuvant cxcr4-CXCL12 Signaling Inhibitor Encapsulated in Synthetic Protein Nanoparticles for Glioma Immunotherapy.
Alghamri MS; Banerjee K; Mujeeb AA; Mauser A; Taher A; Thalla R; McClellan BL; Varela ML; Stamatovic SM; Martinez-Revollar G; Andjelkovic AV; Gregory JV; Kadiyala P; Calinescu A; Jiménez JA; Apfelbaum AA; Lawlor ER; Carney S; Comba A; Faisal SM; Barissi M; Edwards MB; Appelman H; Sun Y; Gan J; Ackermann R; Schwendeman A; Candolfi M; Olin MR; Lahann J; Lowenstein PR; Castro MG
ACS Nano; 2022 Jun; 16(6):8729-8750. PubMed ID: 35616289
[TBL] [Abstract] [Full Text] [Related]
19. Characterising Distinct Migratory Profiles of Infiltrating T-Cell Subsets in Human Glioblastoma.
Kollis PM; Ebert LM; Toubia J; Bastow CR; Ormsby RJ; Poonnoose SI; Lenin S; Tea MN; Pitson SM; Gomez GA; Brown MP; Gargett T
Front Immunol; 2022; 13():850226. PubMed ID: 35464424
[TBL] [Abstract] [Full Text] [Related]
20. Usefulness of 68 Ga-Pentixafor PET/CT on Diagnosis and Management of Cushing Syndrome.
Ding J; Tong A; Hacker M; Feng M; Huo L; Li X
Clin Nucl Med; 2022 Aug; 47(8):669-676. PubMed ID: 35452014
[TBL] [Abstract] [Full Text] [Related]
[Next]
